Givinostat (Duvyzat®). HTA ID: 25048

Assessment Status Pre-submission consultation scheduled
HTA ID 25048
Drug Givinostat
Brand Duvyzat®
Indication Givinostat (Duvyzat®) is indicated for the treatment of Duchenne Muscular Dystrophy in ambulant patients, aged 6 years and older, and with concomitant corticosteroid treatment.
Assessment Process
Rapid review commissioned 05/08/2025
Rapid review completed 14/08/2025
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of givinostat compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/08/2025